Anticoagulants - A Global Market Review

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW AND OUTLOOK
3.MARKET SCENARIO
A Snapshot of Available Therapies
An Insight into Currently Available Antithrombotic Drugs
Weaknesses of Available Therapies
Forces Driving the Market
Oral Anticoagulants Market
Injectable Anticoagulants Market
Heparin Market
LMWH Market
4.MARKET DYNAMICS
Drug Advancements Drive Anticoagulant Market
Niche Markets – The New Target for Drug Makers
An Opportunity to Grow Further
Geriatric Patients – At High Risk of Blood Clots
Improved Anticoagulant Agents for Children Group
Growing Demand for Self-Testing
LMWHs Eases Outpatient Management
Concern Over Underutilization of Warfarin
Anticoagulants to Lose UA/AMI Markets to Antiplatelets
Influx of New Drugs Invigorates the Market
Novel Heparins Enhances Market Potential
Anticoagulant Therapy During Pregnancy Improves Outcomes
New Therapies: Need of the Hour
Anticoagulant Therapy in IPF: Reduces Mortality Risk
Failure of Exanta
5.PRODUCT FACTS
Anticoagulants
Indications for Anticoagulant Use
List of Approved Anticoagulants for Pulmonary Embolism
List of Approved Anticoagulants for Orthopedic Surgery
List of Approved Anticoagulants for General Surgery
List of Approved Anticoagulants for Atrial Fibrillation
List of Approved Anticoagulants for Unstable Angina
List of Approved Anticoagulants for Non-ST Segment Elevation Myocardial Infraction
List of Approved Anticoagulants for Angioplasty Procedures
List of Approved Anticoagulants for HIT Type II
6.DRUG DEVELOPMENT PIPELINE
Select Anticoagulants Under Pipeline
Idraparinux – Sanofi-Aventis
0673 – Sanofi-Aventis
BIBR1048MS - Boehringer Ingelheim
7.CORPORATE DEVELOPMENTS
PAION Acquires CeNes Pharmaceuticals
PAION Announces Acquisition of Global Rights to Trigen’s flovagatran
Biological E Collaborates with Choncept and Heparinex
Bayer’s Market Expansion
B. Braun Recalls Heparin Sodium Based Injection Solutions
Baxter Recalls Heparin Sodium Vials
Boehringer Receives EU Approval for Pradaxa
Sanofi-Aventis Receives Approval for Clexane® in Japan
ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay
Lannett Obtains US FDA Approval for Dipyridamole Tablets
Celgene Acquires Pharmion
BMS Collaborates with Pfizer
Medicines Company Reacquires European Rights for Angiox
HemoSense and LabCorp Sign Agreement for Supply of INRatio System
Sanofi-Aventis Acquires Rights for Panaldine from Daiichi
Alchemia Inks Marketing Alliance with Dr Reddy’s for Heparin
Inverness Announces Acquisition of HemoSense
ev3, FoxHollow Complete Merger
Osmetech Signs Licensing Agreement with Marshfield Clinic
Mitsubishi and Tanabe Agree to Merge
Artisan and A-Bio Form Alliance
Kimball Introduces New Pharmacogenetic Test
Roche Launches an Improved Point-of- Care Anticoagulation Monitoring System
Danish Agency Grants Approval for Anticoagulant Clinical Trials
EMEA Approves ARIXTRA® of GlaxoSmithKline
FDA Approves ANDAs of PLIVA
FDA Approves ARIXTRA Injection of GSK
Japanese Ministry Approves Arixtra of GSK
Eisai Obtains FDA Approval for Fragmin
Sanofi-Aventis' Lovenox® Obtains FDA Approval for Acute Cardiac Care
8.MAJOR PLAYERS
AstraZeneca PLC (UK)
Bristol-Myers Squibb Company (USA)
Celgene Corporation (USA)
GlaxoSmithKline plc (UK)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer Inc. (USA)
Sanofi-Aventis (France)
9.MARKET ANALYTICS
10.THE UNITED STATES
Atrial Fibrillation – A Key Risk Factor
Regulatory Route to the US Market
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Price Controls
US Anticoagulants Market
US Heparin Market
Hinging on Market Opportunities
Generics – Threatening Branded Anticoagulants
List of Patent Protected Anticoagulants in the US
Ignorance – A Major Hindrance
Future Challenges and Growth Drivers
US Emerging Anticoagulant Market
US Emerging Anticoagulants Market: Products in the Pipeline
11.JAPAN
Anticoagulants Market in Japan
Rising Incidence of Pulmonary Thromboembolism
12.EUROPE
a.France
b.Germany
c.Italy
d.The United Kingdom
e.Spain
f.Rest of Europe
13.REST OF WORLD
Table 1: Global Anticoagulants Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 2: Percentage Breakdown of Global Anticoagulants Market by Region for the Years 2008 & 2009
Table 3: Global Oral Anticoagulants Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown of Global Oral Anticoagulants Market by Region for the Years 2008 & 2009
Table 5: Global Injectable Anticoagulants Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Injectable Anticoagulants Market by Region for the Years 2008 & 2009
Table 7: Global Injectable Anticoagulants Market by Segment for the Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Injectable Anticoagulants Market by Segment for the Years 2008 & 2009
Table 9: Global Unfractionated Heparin Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global Unfractionated Heparin Market by Region for the Years 2008 & 2009
Table 11: Global Low Molecular Weight Heparin Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global Low Molecular Weight Heparin Market by Region for the Years 2008 & 2009
Table 13: Anticoagulants Market by Segment in the US: 2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Anticoagulants Market by Segment in the US for the Years 2008 & 2009
Table 15: Anticoagulants Market by Segment in Japan: 2007-2015 (Sales in US$ Million)
Table 16: Percentage Breakdown of Anticoagulants Market by Segment in Japan for the Years 2008 & 2009
Table 17: Anticoagulants Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 18: Percentage Breakdown of Anticoagulants Market by Region in Europe for the Years 2008 & 2009
Table 19: Anticoagulants Market by Segment in Europe: 2007-2015 (Sales in US$ Million)
Table 20: Percentage Breakdown of Anticoagulants Market by Segment in Europe for the Years 2008 & 2009
Table 21: Anticoagulants Market by Segment in France: 2007-2015 (Sales in US$ Million)
Table 22: Percentage Breakdown of Anticoagulants Market by Segment in France for the Years 2008 & 2009
Table 23: Anticoagulants Market by Segment in Germany: 2007-2015 (Sales in US$ Million)
Table 24: Percentage Breakdown of Anticoagulants Market by Segment in Germany for the Years 2008 & 2009
Table 25: Anticoagulants Market by Segment in Italy: 2007-2015 (Sales in US$ Million)
Table 26: Percentage Breakdown of Anticoagulants Market by Segment in Italy for the Years 2008 & 2009
Table 27: Anticoagulants Market by Segment in the UK: 2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Anticoagulants Market by Segment in the UK for the Years 2008 & 2009
Table 29: Anticoagulants Market by Segment in Spain: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Anticoagulants Market by Segment in Spain for the Years 2008 & 2009
Table 31: Anticoagulants Market by Segment in the Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Anticoagulants Market by Segment in the Rest of Europe for the Years 2008 & 2009
Table 33: Anticoagulants Market by Segment in Rest of World: 2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Anticoagulants Market by Segment in Rest of World for the Years 2008 & 2009
Companies Profiled